The primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the help of laboratory (Insulin-like Growth Factor I, Growth Hormone, Oral Glucose-Tolerance Test \[IGF-1, GH, OGTT\]) and instrumental examination methods (Magnetic Resonance Imaging \[MRI\]).
Study Type
OBSERVATIONAL
Enrollment
367
This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
Moscow Board of Health Endocrinology Dispensary
Moscow, Russia
Endocrinology Hospital at First Moscow State Medical University
Moscow, Russia
Percentage of Participants Diagnosed With Acromegaly
Acromegaly is an acquired pathological condition related to excessive production of growth hormone and characterized by somatic disfigurement and multiple systemic manifestations. The percentage of participants with acromegaly was determined in participants with a confirmed clinically significant set of associated somatic disorders using biochemical assays (IGF-1, GH, OGTT) and instrumental examination methods (MRI).
Time frame: Participants were screened over approximately 21 months
Number of Participants Diagnosed With Acromegaly Using Biochemical Assays (IGF-1, GH, OGTT) and Instrumental Examination Methods (MRI)
Acromegaly is an acquired pathological condition related to excessive production of growth hormone and characterized by somatic disfigurement and multiple systemic manifestations. The number of participants with acromegaly was determined in participants with a confirmed clinically significant set of associated somatic disorders using biochemical assays (IGF-1, GH, OGTT) and instrumental examination methods (MRI).
Time frame: Participants were screened over approximately 21 months
Percentage of Participants With Associated Concurrent Somatic Disorders
The percentage of participants with associated concurrent somatic disorders were reported in relation to confirmation of acromegaly diagnosis. Concurrent disorders were prior history of condition or diagnosis.
Time frame: At baseline (Day 1)
Percentage of Participants With Microadenomas and Macroadenomas
Participants were counted as having a microadenomas or macroadenomas if they had at least one microadenoma or macroadenoma during the study. Microadenoma is a benign pituitary tumour size \<=10 millimeter (mm) and macroadenoma is a benign pituitary tumour size \>10 mm. The percentage of participants with microadenomas and macroadenomas registered during pituitary MRI examination were reported.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: Participants were screened over approximately 21 months
Percentage of Participants With the Most Pathognomonic Subjective and Objective Signs for Tracing Acromegaly
Acromegaly diagnosed based on a clinically significant set of associated somatic disorders and was assessed by logistic regression and canonical discriminant analysis. The likelihood of acromegaly diagnosis, based on a clinically significant set of associated somatic disorders (predictors) was assessed by logistic regression and canonical discriminant analysis. To investigate the extent to which each of the somatic disorders poses a risk factor for acromegaly diagnosis, all predictor variables were entered into each analysis. The percentage of participants predicted to have acromegaly or not is presented for the logistic regression analysis and the canonical discriminant analysis.
Time frame: Participants were screened over approximately 21 months